CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with

the United States Postal Service as first-class

Commissioner for Patents, P.O. Box 1450.

October 18, 2006

(Date)

Alexandria, VA 22313-1450, on

AnneMarie Kalser, Reg

an envelope addressed

in



## INFORMATION DISCLOSURE STATEMENT

Goddard, et al.

App. No

10/063,596

Filed

May 3, 2002

For

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

Examiner

Sandra L. Wegert

Art Unit

1647

## ....

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

## Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 14 references to be considered by the Examiner. Also enclosed are 14 non-patent literature references as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed with an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No 11-1410.

Bys

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: (18, 200)

Anne Marie Kaiser

Registration No. 37,649

Attorney of Record Customer No. 30,313

(619) 235-8550

	PTO/SB/08 Equivalent
10/063,596	
May 3, 2002	
Goddard, et al.	
1647	
Sandra L. Wegert	
	May 3, 2002 Goddard, et al. 1647

GNE.3230R1C69

		UMENTS	U.S. PATENT			
mns, Lines Where ssages or Relevant res Appear	Relevant Passa	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Cite No.	Examiner Initials
		vame of Patentee of Applicant	MM-DD-YYYY			

Attorney Docket No.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
			·			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т¹
	1	BERNER, et al., "Clincopathological association of CD44 mRNA and protein expression expression in primary breast carcinomas" <i>Histopathology</i> (2003) 42:546-554.	
	2	BROOKS, et al., "cDNA array identification of genes regulated in rat renal medulla in response to vasoressin infusion" <i>Am J Physiol</i> (2003) 284:F218-F228.	
	3	CONRADS, et al., "A Combined Proteome and Microarray Investigation of Inorganic Phosphate-induced Pre-osteoblast Cells" Mol. Cell Proteomics, 4(9):1284-1296 (2005).	<del></del>
	4	CZUPALLA, et al., "Comparative study of proteinand mRNA expression during osteoclastogenesis" Proteomics 5:3868-3875 (2005).	
	5	GINESTIER, et al. 2002. "Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers" <i>Am. J. Pathol.</i> , 161:1223-1233.	
	6	KAWAMOTO et al., "Expression Profiles of Active Genes in Human and Mouse Livers," <i>Gene</i> , 1996 Sep 26;174(1):151-8.	_
	7	KWONG, et al., "Synchronous global assessment of gene and protein expression in colorectal cancer progression" <i>Genomics</i> , 86:142-158 (2005).	
	8	LEDERMAN, et al. 1991. "A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4." <i>Molecular Immunology</i> , 28(11):1171-1181.	
	9	ODA, et al., "Expression of MDR1/p-glycoprotien and multidrug resistance-associated protein in childhood solid tumours" <i>Virchows Arch</i> (1997) 430:99-105	
	10	SAITO-HISAMINATO et al., Feb. 2002 (Genome-Wide Profiling of Gene Expression in 29 Normal Human Tissues with a cDNA Microarray. DNA Research 9, 35-45.	
	11	QUICO at all 40 de la ministra de la D.O. had not mENA la vela correlate quith differentiation in	

Examiner	Signature	
----------	-----------	--

INFORMATION D. ...
STATEMENT BY APPLICANT

INFORMATION DISCLOSURE

(Multiple sheets used when necessary)

SHEET 1 OF 2

**Date Considered** 

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. Filing Date May 3, 2002 First Named Inventor Goddard, et al. 1647 Art Unit Sandra L. Wege Examiner

10/063,596

GNE.3230R1C69

(Multiple sheets used when necessary) SHEET 2 OF 2

	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>	
	12	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.		
	13	TOLER, et al., "Loss of communication in ovarian cancer" American Journal of Obstertrics and Gynecology, (2006)194:e27-e31.		
	14	WASHBURN, et al., "Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae" Proc. Natl. Acad. Sci. 100(6): 3107-3112. (2003)		

Attorney Docket No.

3030521:101806/JJH

**Examiner Signature** 

**Date Considered** 

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.